Seres Therapeutics
Cash Flow
Last updated:
Cash flow statement presents a set of outflows and inflows of cash within a company through operating, investing and financing activities. Over the last year, operating activities of Seres Therapeutics generated cash of -$117,354,000, which is more than the previous year. Cash used in financing activities reached the amount of $71,705,000 last year. Net change in cash is therefore -$35,065,000.
Cash Flow
| 2014 | -10.35M | -1.10M | 123.99M |
|---|---|---|---|
| 2015 | -40.84M | -137.13M | 137.72M |
| 2016 | 43.92M | -65.45M | 2.13M |
| 2017 | -75.52M | 56.98M | 83K |
| 2018 | -62.85M | 112.31M | 268K |
| 2019 | -76.52M | -30.51M | 86.23M |
| 2020 | -93.61M | -158.89M | 303.42M |
| 2021 | 6.68M | 64.08M | 1.17M |
| 2022 | -228.81M | 82.42M | 129.60M |
| 2023 | -117.35M | 10.58M | 71.70M |
MCRB Cash Flow Statement (2014 – 2023)
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | |
|---|---|---|---|---|---|---|---|---|---|---|
Cash at beginning of period | 171.21M | 188.00M | 116.04M | 65.12M | 85.93M | 36.20M | 54.53M | 73.93M | 114.18M | 1.65M |
Operating activities | ||||||||||
Net income | -113.72M | -250.15M | -65.57M | -89.12M | -70.27M | -98.94M | -89.38M | -91.57M | -54.78M | -16.70M |
| Adjustments to reconcile net income to cash generated by operating activities: | ||||||||||
Depreciation and amortization | 6.24M | 6.62M | 5.94M | 6.57M | 7.60M | 7.86M | 7.25M | 4.20M | 728K | 190K |
Stock-based compensation expense | 34.10M | 25.48M | 20.22M | 8.82M | 8.34M | 0 | 17.36M | 16.85M | 9.69M | 2.06M |
| Deferred income tax benefit | 34.10M | 25.48M | 20.22M | 8.82M | 8.34M | 0 | 17.36M | 16.85M | 9.69M | 2.06M |
| Changes in operating assets and liabilities: | ||||||||||
Accounts receivable, net | -8.67M | 0 | 9.38M | -7.60M | -1.78M | 0 | 0 | 0 | 0 | 0 |
Inventories | -29.64M | 0 | 27.13M | -2.87M | -3.86M | 0 | 0 | 0 | 0 | 0 |
Accounts payable | -11.57M | 2.20M | 9.36M | -1.15M | -1.46M | -353K | -856K | 3.58M | 2.68M | 810K |
Cash generated by operating activities | -117.35M | -228.81M | 6.68M | -93.61M | -76.52M | -62.85M | -75.52M | 43.92M | -40.84M | -10.35M |
Investing activities | ||||||||||
Purchases Of Investments | -4.42M | -48.22M | -95.97M | -218.28M | -46.42M | -21.83M | -96.53M | -290.59M | -267.76M | 0 |
Investments In Property Plant And Equipment | -7.97M | -9.82M | -9.56M | -591K | -1.00M | -1.93M | -4.67M | -21.49M | -4.36M | -1.00M |
Acquisitions Net | 0 | -92.24M | -73.65M | 19.9M | 29.51M | 0 | 0 | 0 | 0 | 0 |
Cash generated by investing activities | 10.58M | 82.42M | 64.08M | -158.89M | -30.51M | 112.31M | 56.98M | -65.45M | -137.13M | -1.10M |
Financing activities | ||||||||||
Common Stock Issued | 18.15M | 101.16M | 827K | 303.42M | 61.21M | 61K | 0 | 2.13M | 143.01M | 5K |
Payments for dividends | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repurchases of common stock | 0 | 0 | 0 | 0 | 0 | -197K | -33K | 0 | -24K | 0 |
Repayments of term debt | 50.51M | 25.69M | -948K | -19.9M | 25M | 0 | 0 | 0 | -2.6M | -400K |
Cash used in financing activities | 71.70M | 129.60M | 1.17M | 303.42M | 86.23M | 268K | 83K | 2.13M | 137.72M | 123.99M |
Net Change In Cash | -35.06M | -16.78M | 71.95M | 50.92M | -20.80M | 49.73M | -18.45M | -19.39M | -40.25M | 112.53M |
Cash at end of period | 136.15M | 171.21M | 188.00M | 116.04M | 65.12M | 85.93M | 36.08M | 54.53M | 73.93M | 114.18M |
| Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source |